CAS: 73310-10-8; Eicosapentaenoic Acid Ethyl Ester

该化合物是一种纯净的乙酯衍生物,其衍生物为乙型乙酰乙酰乙酰乙酸,一种亚丙烯酸,一种亚丙酰-3脂肪酸,其特点是其高度稳定性,生物利用率提高和溶性比免费脂肪酸形式高.EPA-EE广泛用于药物和营养色学应用,因为其记录精密的心血管和防炎效果.乙基酯配方确保长期的储存寿命,并促进临床环境的标准化剂量.其分子结构允许将高效的代谢纳入细胞膜,支持脂质调制和炎症反应条例.EPA-EA严格地测试其纯度,使之适合于需要精确脂肪酸特征的研究和治疗配方.

结构式图片

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-10005720-B2
    优先权日:2013-04-05
    标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same
    发明人:SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L
    权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL
    摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

    专利号:US-11512097-B2
    优先权日:2019-11-25
    标题 :Heterocyclic compounds as Delta-5 desaturase inhibitors and methods of use
    发明人:ALLEN JENNIFER R; BELTRANI MICHELA; BOURBEAU MATTHEW P; DAMYANOVA TEODORA P; LINGARD IAIN; MINATTI ANA E; VINCETTI PAOLO
    权利人:AMGEN INC
    摘要:The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase (“D5D†). The compounds have a general Formula I n nwherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

    专利号:US-9365482-B2
    优先权日:2013-02-28
    标 题:Methods of preparing fatty acid derivatives
    发明人:SKJAERET TORE; HOVLAND RAGNAR
    权利人:PRONOVA BIOPHARMA NORGE AS
    摘要:Methods for the efficient synthesis of fatty acid derivatives and their intermediates are provided.

    专利号:WO-2023106793-A1
    优先权日:2021-12-07
    标题 :Method for producing high-purity triglyceride derivatives containing high content of eicosapentaenoic acid (epa)
    发明人:KIM HYUNG SANG; KIM JAE HAN; NAM DONG HYUK; KIM JAEEUN; LEE SEUNG UK; KANG SUNG KWON; PARK SHIN JUNG
    权利人:CHONG KUN DANG PHARMACEUTICAL CORP
    摘要:The present invention relates to a method for preparing high-content and high-purity omega-3 triglyceride comprising synthesizing under vacuum conditions by using omega-3 fatty acid ethyl ester, glycerol, and enzyme. The method for preparing of the present invention is a method for efficiently mass-producing third generation omega-3 triglyceride, which has improved the problem of low concentration of an active ingredient of first generation omega-3 and the problem of stability and bioavailability of second generation omega-3. Specifically, the method for preparing of the present invention is a mass-production synthesis method that minimizes processing processes by using processed enzyme differentiated from previous experiments to improve reactivity, and by maximizing reaction efficiency under conditions differentiated from previous experiments, and may provide omega-3 triglyceride in which a purity of triglyceride of single omega-3 fatty acid is 70% or more and a content of single omega-3 is 80% or more. High-content and high-purity omega-3 triglyceride according to the present invention may be advantageously used as a medicine, food, a main raw material or supplementary material of food, a food additive, functional food or beverage.

    专利号:US-2018370905-A1
    优先权日:2013-04-05
    标题:Compounds Useful for the Treatment of Metabolic Disorders and Synthesis of the Same

    专利号:US-2013190399-A1
    优先权日:2009-10-31
    标 题:Synthesis and use of omega-3 and omega 6 very long chain polyunsaturated fatty acids (VLC-PUFA)
    发明人:RAMAN KRISHNA; TARWADE VINOD
    权利人:RAMAN KRISHNA; TARWADE VINOD; MARTEK BIOSCIENCES CORP
    摘要:The invention provides methods of synthesizing omega-3 and omega-6 very long chain polyunsaturated fatty acids (VLC-PUFAs, C28-C42:4, 5 and 6), analogs and derivatives thereof, pharmaceutical compositions containing these isolated VLC-PUFA compounds and therapeutic uses therefor.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.1007/s10157-011-0485-2
    摘要:Shiohira S, Yoshida T, Sugiura H, Yoshida S, Mitobe M, Shimada K, Ohba T, Tsuchiya K, Kabaya T, Nitta K. Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients. Clinical and Experimental Nephrology. 2011 Jul 20;15(6):893–9. doi: 10.1007/s10157-011-0485-2.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知